Impact of recombinant PTH on management of hypoparathyroidism: a systematic review
Tóm tắt
The treatment of post-surgical hypoparathyroidism (following thyroid or parathyroid surgery) is challenging. Presently, this condition is treated with calcium and vitamin D supplements rather than replacing the missing parathyroid hormone. Not only is it challenging to maintain normocalcaemia, but concerns of hypercalciuria and ectopic calcification have also been raised using these supplements. There is an ongoing
debate whether recombinant parathyroid hormone (rPTH), which as yet is unlicensed for treating hypoPTH, may offer a more physiological solution. The objective of the study was to assess the effectiveness and safety of rPTH in maintaining normocalcaemia and normocalcuria in hypoparathyroidism. This was a systematic review performed using independently developed search strategies including Medline, Embase, CINAHL, Cochrane, Zetoc, conference proceedings and a manual search until 15 July 2014. Data extraction was undertaken by one reviewer (YR). Studies were synthesised through narrative review with tabulation of results. Of 2,141 studies identified, only eleven studies fitted the inclusion criteria. These studies suggest that rPTH is useful in normalising serum calcium levels. Excretion of urinary calcium levels is reduced with PTH 1–34 but remained unchanged in a number of studies using PTH 1–84. Recombinant PTH is well tolerated. The majority of studies included post-surgical hypoparathyroidism with marked heterogeneity. Further prospective, larger, long-term trials are necessary to evaluate the long-term efficacy and adverse profile of rPTH, including head to head comparisons between PTH 1–34 and PTH 1–84.
Tài liệu tham khảo
Powers J, Joy K, Ruscio A, Lagast H (2013) Prevalence and incidence of hypoparathyroidism in the United States using a large claims database. J Bone Miner Res Off J Am Soc Bone Miner Res 28(12):2570–2576
Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L (2013) Cardiovascular and renal complications to postsurgical hypoparathyroidism: a Danish nationwide controlled historic follow-up study. J Bone Miner Res Off J Am Soc Bone Miner Res 28(11):2277–2285
Christiansen C, Rødbro P, Christensen MS, Hartnack B, Transbøl I (1978) Deterioration of renal function during treatment of chronic renal failure with 1,25-dihydroxycholecalciferol. Lancet 2(8092 Pt 1):700–703
Santos F, Smith MJ, Chan JC (1986) Hypercalciuria associated with long-term administration of calcitriol (1,25-dihydroxyvitamin D3). Action of hydrochlorothiazide’. Am J Dis Child 140(2):139–142
Weber G, Cazzuffi MA, Frisone F, de Angelis M, Pasolini D, Tomaselli V, and Chiumello G (1989 1988) Nephrocalcinosis in children and adolescents: sonographic evaluation during long-term treatment with 1,25-dihydroxycholecalciferol Child Nephrol Urol 9(5):273–276
Albright F, Ellsworth R (1929) Studies on the physiology of the parathyroid glands: I. Calcium and phosphorus studies on a case of idiopathic hypoparathyroidism. J Clin Invest 7(2):183–201
Melick RA, Gill JR Jr, Berson SA, Yalow RS, Bartter FC, Potts JT Jr, Aurbach GD (1967) Antibodies and clinical resistance to parathyroid hormone. N Engl J Med 276(3):144–147
Sikjaer T, Rejnmark L, Mosekilde L (2011) PTH treatment in hypoparathyroidism. Curr Drug Saf 6(2):89–99
Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, Westmore MS, Linda Y, Nold JB (2002) Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1–34) for 2 years and relevance to human safety. Toxicol Pathol 30(3):312–321
Winer KK, Yanovski JA, Sarani B, Cutler GB Jr (1998) A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone 1–34 in treatment of hypoparathyroidism. J Clin Endocrinol Metab 83(10):3480–3486
Winer KK, Yanovski JA, Cutler GB (1996) Synthetic human parathyroid hormone 1–34 vs calcitriol and calcium in the treatment of hypoparathyroidism. JAMA J Am Med Assoc 276(8):631–636
Winer KK, Zhang B, Shrader JA, Peterson D, Smith M, Albert PS, Cutler GB (2012) Synthetic human parathyroid hormone 1–34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism. J Clin Endocrinol Metab 97(2):391–399
Winer KK, Sinaii N, Reynolds J, Peterson D, Dowdy K, Cutler GB (2010) Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1–34 versus calcitriol and calcium. J Clin Endocrinol Metab 95(6):2680–2688
Winer KK, Sinaii N, Peterson D, Sainz B, Cutler GB (2008) Effects of once versus twice-daily parathyroid hormone 1–34 therapy in children with hypoparathyroidism. J Clin Endocrinol Metab 93(9):3389–3395
Winer KK, Ko CW, Reynolds JC, Dowdy K, Keil M, Peterson D, Gerber LH, McGarvey C, Cutler GB (2003) Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1–34) versus calcitriol and calcium. J Clin Endocrinol Metab 88(9):4214–4220
Winer KK, Fulton KA, Albert PS, Cutler GB (2014) Effects of Pump versus Twice-Daily Injection Delivery of Synthetic Parathyroid Hormone 1–34 in Children with Severe Congenital Hypoparathyroidism. J Pediatr 165:556–563
Sikjaer T, Rejnmark L, Rolighed L, Heickendorff L, Mosekilde L, Hypoparathyroid Study Group (2011) The effect of adding PTH(1–84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study. J Bone Miner Res Off J Am Soc Bone Miner Res 26(10):2358–2370
Mannstadt M, Clarke BL, Vokes T, Brandi ML, Ranganath L, Fraser WD, Lakatos P, Bajnok L, Garceau R, Mosekilde L, Lagast H, Shoback D, Bilezikian JP (2013) Efficacy and safety of recombinant human parathyroid hormone (1–84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study. Lancet Diabetes Endocrinol 1(4):275–283
Sikjaer T, Rejnmark L, Rolighed L, Heickendorff L, Mosekilde L (2011) The effect of adding PTH(1–84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study. J Bone Miner Res 26(10):2358–2370
Rubin MR, Sliney J, McMahon DJ, Silverberg SJ, Bilezikian JP (2010) Therapy of hypoparathyroidism with intact parathyroid hormone. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA 21(11):1927–1934
Cusano NE, Rubin MR, McMahon DJ, Zhang C, Ives R, Tulley A, Sliney J, Cremers SC, Bilezikian JP (2013) Therapy of hypoparathyroidism with PTH(1–84): a prospective four-year investigation of efficacy and safety. J Clin Endocrinol Metab 98(1):137–144
Puig-Domingo M, Díaz G, Nicolau J, Fernández C, Rueda S, Halperin I (2008) Successful treatment of vitamin D unresponsive hypoparathyroidism with multipulse subcutaneous infusion of teriparatide. Eur J Endocrinol Eur Fed Endocr Soc 159(5):653–657
Sikjaer T, Rolighed L, Hess A, Fuglsang-Frederiksen A, Mosekilde L, Rejnmark L (2014) Effects of PTH(1–84) therapy on muscle function and quality of life in hypoparathyroidism: results from a randomized controlled trial. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA 25(6):1717–1726
Cusano NE, Rubin MR, McMahon DJ, Irani D, Anderson L, Levy E, Bilezikian JP (2014) PTH(1–84) is associated with improved quality of life in hypoparathyroidism through 5 years of therapy. J Clin Endocrinol Metab. doi:10.1210/jc.2014-2267
Ramanau H, Rudenka E (2010) Bone mineral density in young male patients with postoperative hypoparathyroidism after thyroidectomy. Osteoporos Int 21:S317–S318
Pereira FDA, Mendonca ML, Nogueira-Barbosa MH, Watanabe PCA, Teixeira SR, Maciel LM, De FJA (2011) Hypoparathyroidism (HP) protects bone mass but is highly associated with lumbar morphometric fracture. Bone 48:S206
Rubin MR, Dempster DW, Sliney J, Zhou H, Nickolas TL, Stein EM, Dworakowski E, Dellabadia M, Ives R, McMahon DJ, Zhang C, Silverberg SJ, Shane E, Cremers S, Bilezikian JP (2011) PTH(1–84) administration reverses abnormal bone-remodeling dynamics and structure in hypoparathyroidism. J Bone Miner Res Off J Am Soc Bone Miner Res 26(11):2727–2736
Rubin MR, Sliney J, McMahon DJ, Silverberg SJ, Bilezikian JP (2010) Therapy of hypoparathyroidism with intact parathyroid hormone. Osteoporos Int 21(11):1927–1934
Newfield RS (2007) Recombinant PTH for initial management of neonatal hypocalcemia. N Engl J Med 356(16):1687–1688
Linglart A, Rothenbuhler A, Gueorgieva I, Lucchini P, Silve C, Bougneres P (2011) Long-term results of continuous subcutaneous recombinant PTH (1–34) infusion in children with refractory hypoparathyroidism. J Clin Endocrinol Metab 96(11):3308–3312
Theman TA, Collins MT, Dempster DW, Zhou H, Reynolds JC, Brahim JS, Roschger P, Klaushofer K, Winer KK (2009) PTH(1–34) replacement therapy in a child with hypoparathyroidism caused by a sporadic calcium receptor mutation. J Bone Miner Res Off J Am Soc Bone Miner Res 24(5):964–973
Subbiah V, Madsen VS, Raymond AK, Benjamin RS, Ludwig JA (2010) Of mice and men: divergent risks of teriparatide-induced osteosarcoma. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA 21(6):1041–1045
Cosman F, Lane NE, Bolognese MA, Zanchetta JR, Garcia-Hernandez PA, Sees K, Matriano JA, Gaumer K, Daddona PE (2010) Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women. J Clin Endocrinol Metab 95(1):151–158
Liu D, Zhu Y, Yang C, Long J, Yao C, Li J, Wang S (2012) Potential treatment of hypoparathyroidism with recombinant plasmids encoding preproparathyroid hormone. J Endocrinol Invest 35(5):479–484